Rylan Hanks serves as the Executive Director of Regulatory Strategy at Neurocrine Biosciences, where he plays a pivotal role in shaping the regulatory landscape for innovative therapies. With a strong focus on neuroimmunology, Rylan is the Global Regulatory Lead for INGREZZA, a groundbreaking treatment for...
Rylan Hanks serves as the Executive Director of Regulatory Strategy at Neurocrine Biosciences, where he plays a pivotal role in shaping the regulatory landscape for innovative therapies. With a strong focus on neuroimmunology, Rylan is the Global Regulatory Lead for INGREZZA, a groundbreaking treatment for tardive dyskinesia. His extensive knowledge of global legislative and regulatory requirements allows him to navigate complex regulatory pathways, ensuring that Neurocrine’s products meet the highest standards of safety and efficacy.
In his current role, Rylan spearheads key projects that involve the development and implementation of regulatory strategies across multiple therapeutic areas. His expertise in regulatory guidelines and documentation is instrumental in aligning the company’s objectives with the evolving dynamics of health policy and regulatory frameworks. Rylan’s ability to distill complex regulatory information into actionable insights empowers cross-functional teams to make informed decisions that drive drug development forward.
Rylan’s background in pharmacy and deep understanding of both drugs and devices enable him to effectively advocate for Neurocrine’s interests in various regulatory forums. His commitment to policy research and community pharmacy initiatives further enhances his ability to influence health outcomes on a broader scale. As a leader in the pharmaceutical industry, Rylan Hanks exemplifies a goal-oriented approach, leveraging his skills in legislation and regulatory intelligence to navigate the intricacies of the healthcare landscape and ensure that innovative therapies reach the patients who need them most.
